GROWTH HORMONE RESPONSE TO LOW DOSE INTRAVENOUS INJECTIONS OF GROWTH HORMONE RELEASING FACTOR IN OBESE AND NORMAL WEIGHT WOMEN
- 1 February 1986
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 24 (2) , 157-164
- https://doi.org/10.1111/j.1365-2265.1986.tb00758.x
Abstract
We have recently reported an impaired growth hormone (GH) response to a single i.v. bolus dose of growth hormone releasing factor (1 .mu.g/kg body weight) in obese women. We have now investigated whether the i.v. administration of low dose GHRF(1-29)NH2 (0.33 .mu.g/kg/h) by 15 min pulsed injections for 3 h followed by an i.v. bolus (1 .mu.g/kg) to four normal weight women and six obese women results in an enhancement of GH release. In the control women low dose GHRF, given either as a single 10 .mu.g injection or in pulses of equivalent total dosage, produced a GH response identical to that seen after a single bolus of 60 .mu.g (mean peak GH low dose 30 .+-. 2 mU/l, peak GH large dose 30 .+-. 0.5 mU/l). In the obese women GH release was significantly less than the controls after low doses of GHRF (P < 0.01) and the peak was delayed compared to that following a single large bolus dose (peak GH 7 .+-. 1.2 mU/l). However, three of the obese women who previously showed no response to a large dose of GHRF did release GH after low dose pulsed injections. The final bolus of GHRF after 3 h of pulsed injections did not elicit any additional GH release in the subjects irrespective of body weight. We conclude that obesity may be characterized by impaired GH release to i.v. GHRF. The finding that some obese women do not respond to a single large dose injection of GHRF but do release GH after low dose pulsed injections supports the hypothesis of a hypothalamic disorder in these women. Further studies are needed to determine the clinical efficacy of low dose GHRF.This publication has 19 references indexed in Scilit:
- IMPAIRED GROWTH HORMONE RESPONSE TO GROWTH HORMONE RELEASING FACTOR AND INSULIN‐HYPOGLYCAEMIA IN OBESITYClinical Endocrinology, 1985
- 46 USE OF GRF(1–29) FOR GROWTH HORMONE STIMULATIONPediatric Research, 1985
- Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.Journal of Clinical Investigation, 1985
- Growth hormone releasing factor infusion does not sustain elevated GH-levels in normal subjectsActa Endocrinologica, 1984
- RESPONSES TO ANALOGUES OF GROWTH HORMONE-RELEASING HORMONE IN NORMAL SUBJECTS, AND IN GROWTH-HORMONE DEFICIENT CHILDREN AND YOUNG ADULTSClinical Endocrinology, 1984
- Stimulation of Growth Hormone (GH) and Somatomedin C in Idiopathic GH-Deficient Subjects by Intermittent Pulsatile Administration of Synthetic Human Pancreatic Tumor GH-Releasing Factor*Journal of Clinical Endocrinology & Metabolism, 1984
- SomatostatinNew England Journal of Medicine, 1983
- EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCYThe Lancet, 1983
- Persistence of defective hypothalamic control of prolactin secretion in some obese women after weight reduction.BMJ, 1980
- Growth Hormone: Independent Release of Big and Small Forms from Rat Pituitary in VitroScience, 1975